The Latest Breaking News from AstraZeneca

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.24% on an annualized basis producing an average annual return of 17.72%. Currently, AstraZeneca has a market capitalization of $213.61 billion.

'The longer-term protection against hospitalisation and death is perhaps the most important factor for future booster programmes'

The study compared immune responses to seven vaccines used as a booster 28 days after two initial doses.

AstraZeneca plc (NASDAQ:AZN) shared detailed results from the PROVENT Phase 3 pre-exposure prophylaxis (prevention) trial of Evusheld (tixagevimab and cilgavimab), formerly AZD7442. The data showed that Evusheld reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and 83% in the six-month follow-up analysis, compared to placebo.  There were no…

Shares in the FTSE 250 company slumped as much as 10% as it warned revenues will be lower this year than last

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new COVID vaccine. VLA2001 is manufactured by French pharmaceutical company Valneva for use in the UK and was approved on April 14 for use in adults between the ages of 18 and 50 for first and second doses.

It is the sixth Covid-19 vaccine to be granted an MHRA authorisation for use in Britain

GlaxoSmithKline’s drug aimed at chronic kidney disease patients with anaemia and AstraZeneca’s lung cancer treatment have both moved a step closer to getting the green light

There's been an explosion in vaccine research - as an oral Covid-19 inoculation is tested in the US, Jane Symons asks if no-jab vaccines could be the future of immunisation

A prominent Thai politician faces up to 20 years in prison following his indictment on Monday for insulting the king and violating a cyber law, after he criticised the government for over-reliance on a royal-owned firm to supply COVID-19 vaccines.

Manufacturing of the vaccine has slowed and further research is stalled